Evidence map›Paper›PMID 40162078›Full record

ArticleJournal of inflammation research2025

A Matrigel-Free 3D Chondrocytic Spheroid Model for Rheumatoid Arthritis-Associated Synoviocytes Invasion Studies.

Yingjie Zhao, Xuezhi Yang, Feng Yao, Ziwei Ouyang, Weirong Hu, Lin Li, Juan Cheng, Ke Wang, Jie Ding, Liang Zheng and 7 more

Abstract read
In one paragraph

Article in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Yingjie Zhao *Department of Clinical Pharmacology, The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, 230601, People's Republic of China.ORCID 0000-0001-9892-3732
Xuezhi Yang *Institute of Clinical Pharmacology, Anhui Medical University, Hefei, Anhui, 230032, People's Republic of China.
Feng Yao *Department of Clinical Pharmacology, The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, 230601, People's Republic of China.
Ziwei OuyangInflammation and Immune Mediated Diseases Laboratory of Anhui Province, Anhui Institute of Innovative Drugs, School of Pharmacy, Anhui Medical University, Hefei, Anhui, 230032, People's Republic of China.
Weirong HuInflammation and Immune Mediated Diseases Laboratory of Anhui Province, Anhui Institute of Innovative Drugs, School of Pharmacy, Anhui Medical University, Hefei, Anhui, 230032, People's Republic of China.
Lin LiDepartment of Rheumatology and Immunology, The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, 230601, People's Republic of China.
Juan ChengDepartment of Laboratory Medicine, The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, 230601, People's Republic of China.
Ke WangDepartment of Clinical Pharmacology, The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, 230601, People's Republic of China.
Jie DingInflammation and Immune Mediated Diseases Laboratory of Anhui Province, Anhui Institute of Innovative Drugs, School of Pharmacy, Anhui Medical University, Hefei, Anhui, 230032, People's Republic of China.
Liang ZhengDepartment of Clinical Pharmacology, The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, 230601, People's Republic of China.
Biao QuDepartment of Clinical Pharmacology, The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, 230601, People's Republic of China.
Cheng SunInflammation and Immune Mediated Diseases Laboratory of Anhui Province, Anhui Institute of Innovative Drugs, School of Pharmacy, Anhui Medical University, Hefei, Anhui, 230032, People's Republic of China.
Shufang LiDepartment of Clinical Pharmacology, The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, 230601, People's Republic of China.
Chen JiangInflammation and Immune Mediated Diseases Laboratory of Anhui Province, Anhui Institute of Innovative Drugs, School of Pharmacy, Anhui Medical University, Hefei, Anhui, 230032, People's Republic of China.
Yanan ChenInflammation and Immune Mediated Diseases Laboratory of Anhui Province, Anhui Institute of Innovative Drugs, School of Pharmacy, Anhui Medical University, Hefei, Anhui, 230032, People's Republic of China.
Renpeng ZhouDepartment of Clinical Pharmacology, The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, 230601, People's Republic of China.
Wei HuDepartment of Clinical Pharmacology, The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, 230601, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The primary pathology of rheumatoid arthritis (RA) involves the invasion of the extracellular matrix (ECM) of articular cartilage by inflammation-activated fibroblast-like synoviocytes (FLS), a process targeted by most RA therapeutic drugs. However, the absence of an efficient in vitro model for evaluating FLS invasion hinders relevant drug screening and mechanism research. To address this, a novel three-dimensional (3D) chondrocytic spheroid model that mimics cartilage ECM has been developed, along with corresponding indices to quantify synoviocytes invasion. Methods: The matrigel-free 3D chondrocytic spheroid model was developed using an ultra-low attachment plate. The model was characterized using transcriptome sequencing, immunofluorescent staining. To explore the feasibility of this 3D chondrocytic spheroid model for evaluating the invasive capacity of synoviocytes, multi-interference strategies, including Results: The 3D culture environment is more suitable for cartilage ECM synthesis by increasing cartilage anabolism-related gene ( Conclusion: This matrigel-free 3D chondrocytic spheroid model offers an ideal platform for innovative drug screening and pathogenesis studies focused on synoviocytes invasion of cartilage.

Indexed as

3Dchondrocytesdrug screening modelinvasionRAsynoviocytes

Identifiers

PMID40162078
PMCPMC11952051

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.